AlphaRx selects ARX82 for advanced preclin development
Canada's AlphaRx, a specialty pharmaceutical company, says that its ARX828, an orally-administered, potent and selective inhibitor of inducible nitric oxide synthase, is advancing to preclinical studies to support an Investigational New Drug application in 2008.
In animal models of inflammation, the anti-inflammatory activity of ARX828 is significantly higher than indomethacin and as effective as dexamethasone (a steroidal drug), but without the side-effects associated with either of these agents.
The company has initiated two pivotal animal studies for ARX828 and expects to receive results from these for analysis, by end of November. AlphaRx says its goal is to develop ARX828 for the treatment of rheumatoid arthritis and inflammatory bowel disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze